IL-2-R beta expression and function within resting CD8+ T cells preferentially segregate with the CD45R0+ subset.
Human peripheral blood CD8+ T cells constitutively express a low level of IL-2-R beta chains which were shown in this study to be preferentially carried by the CD45R0+ subset. Such receptors can transduce signals for in vitro IL-2-induced cytolytic function and for the initiation of soluble anti-CD3 and IL-2-induced cell proliferation. Using these stimulation models, a comparison was made between the responsiveness of resting, small CD45R0+ and CD45RA+ subpopulations of CD8+ T cells, both of them being isolated by negative selection and rigorously depleted of monocytes and of IL-2-inducible non-MHC-restricted CTL. Strong proliferation was induced in CD8+/CD45R0+ cells in response to IL-2 and soluble anti-CD3 (each of these stimuli being by itself ineffective), while in contrast, CD8+/CD45RA+ cells manifested, in this system, little reactivity. Accordingly, no conversion to the CD45R0 phenotype occurred in single stained CD45RA+ T cells following their incubation with the stimuli. A similar restriction of reactivity to CD8+/CD45R0+ T cells was observed with respect to IL-2-induced targetable T cell cytotoxicity. The CTL activity induced by IL-2 alone occurred without cell division. In contrast, the additional increase in CTL activity occurring upon the synergistic actions of anti-CD3 mAb and IL-2 coincided with intense cell proliferation, with no generation of LAK activity. The inhibition exerted by anti-IL-2-R beta mAb in the cytolytic and the proliferative activities induced by these stimuli in resting CD8+/CD45R0+ T cells emphasizes the importance of constitutive IL-2-R beta chains in the biology of these cells.
Moire
N
N
Laboratoire d'Immunologie Cellulaire et de Transplantation, Institut de Recherches Scientifiques sur le Cancer, Villejuif, France.
Rouleau
M
M
Metivier
D
D
Charpentier
B
B
Senik
A
A
D015703:Antigens, CD / Q000276:immunology*; D002453:Cell Cycle; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D006649:Histocompatibility Antigens / Q000276:immunology*; D006801:Humans; D017493:Leukocyte Common Antigens; D008562:Membrane Glycoproteins / Q000276:immunology*; D015375:Receptors, Interleukin-2 / Q000378:metabolism / Q000502:physiology*; D015398:Signal Transduction; D016176:T-Lymphocyte Subsets; D013602:T-Lymphocytes, Cytotoxic; D050378:T-Lymphocytes, Regulatory / Q000378:metabolism*
D015703:Antigens, CD; D006649:Histocompatibility Antigens; D008562:Membrane Glycoproteins; D015375:Receptors, Interleukin-2; D017493:Leukocyte Common Antigens